Grace Therapeutics, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Grace Therapeutics, Inc. (GRCE) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of -$900.00 thousand for the 12-month period ending 2026-03-31, per its 10-K filed 2026-06-18.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2026-06-18
- Grace Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-03-31 was $0.00.
- Grace Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-12-31 was $40.00K, a 96.60% decline year-over-year.
- Grace Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-09-30 was -$1.43M.
- Grace Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-06-30 was $487.00K.
- Grace Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2026 was -$900.00K.
- Grace Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2025 was -$3.22M, a 217.96% decline from fiscal 2024.
- Grace Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2024 was $2.73M.
- Grace Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2023 was -$10.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month as first filed |
|---|---|---|---|---|---|
| 2026-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-18 | $40.00K derived: sum of 2 quarters · filed 2026-06-18 | -$1.39M derived: sum of 3 quarters · filed 2026-06-18 | -$900.00K 10-K · filed 2026-06-18 | |
| 2025-12-31 | $40.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-12 | -$1.39M derived: sum of 2 quarters · filed 2026-02-12 | -$900.00K 10-Q · filed 2026-02-12 | -$3.54M derived: sum of 4 quarters · filed 2026-06-18 | |
| 2025-09-30 | -$1.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | -$940.00K 10-Q · filed 2025-11-13 | -$3.58M derived: sum of 3 quarters · filed 2026-06-18 | -$2.40M derived: sum of 4 quarters · filed 2026-06-18 | |
| 2025-06-30 | $487.00K 10-Q · filed 2025-08-12 | -$2.15M derived: sum of 2 quarters · filed 2026-06-18 | -$975.00K derived: sum of 3 quarters · filed 2026-06-18 | -$1.34M derived: sum of 4 quarters · filed 2026-06-18 | |
| 2025-03-31 | -$2.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-18 | -$1.46M derived: sum of 2 quarters · filed 2026-06-18 | -$1.82M derived: sum of 3 quarters · filed 2026-06-18 | -$3.22M 10-K · filed 2026-06-18 | $3.22M 10-K · filed 2025-06-23 |
| 2024-12-31 | $1.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-12 | $817.00K derived: sum of 2 quarters · filed 2026-02-12 | -$578.00K 10-Q · filed 2026-02-12 | $449.00K derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-09-30 | -$361.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | -$1.76M 10-Q · filed 2025-11-13 | -$729.00K derived: sum of 3 quarters · filed 2025-11-13 | -$854.00K derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | -$1.40M 10-Q · filed 2025-08-12 | -$368.00K derived: sum of 2 quarters · filed 2025-08-12 | -$493.00K derived: sum of 3 quarters · filed 2025-08-12 | $1.33M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-23 | $902.00K derived: sum of 2 quarters · filed 2025-06-23 | $2.73M derived: sum of 3 quarters · filed 2025-06-23 | $2.73M 10-K · filed 2025-06-23 | |
| 2023-12-31 | -$125.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-13 | $1.70M derived: sum of 2 quarters · filed 2025-02-13 | $1.70M 10-Q · filed 2025-02-13 | $1.70M derived: sum of 4 quarters · filed 2025-02-13 | |
| 2023-09-30 | $1.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-13 | $1.83M 10-Q · filed 2024-11-13 | $1.83M derived: sum of 3 quarters · filed 2024-11-13 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-09 | $0.00 derived: sum of 2 quarters · filed 2024-08-09 | |||
| 2023-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-21 | -$10.00K 10-K · filed 2024-06-21 | |||
| 2022-12-31 | -$10.00K 10-Q · filed 2024-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |